)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Prime Medicine
Prime Medicine (PRME) investor relations material
Prime Medicine Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Q3 2026 net loss narrowed to $39.0M from $50.6M YoY; 9M net loss was $130.3M versus $155.1M.
Pipeline advanced into clinical development: PM577a’s first patient was dosed in October, while PM647 received FDA IND clearance in September; initial data for both are expected in 2027.
Financial highlights
Q3 collaboration revenue was $4.2M versus $1.2M YoY; 9M revenue was $6.2M versus $3.8M, with no product-sale revenue to date.
Q3 operating expenses were $44.1M versus $55.2M; operating loss was $39.9M versus $54.0M. 9M expenses were $140.1M versus $163.5M.
9M operating cash use was $120.4M; cash, cash equivalents and short-term investments were $61.2M at September 30, excluding restricted cash.
Outlook and guidance
Existing cash, cash equivalents and investments, including November offering proceeds, are expected to fund operating expenses and capital needs through 2027; the estimate relies on assumptions that may prove incorrect.
Initial clinical data for PM577a and PM647 are expected in 2027; a BLA submission for PM359 is planned for H1 2027.
Operating losses and negative operating cash flows are expected for the foreseeable future; R&D spending may rise as trials and development advance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Prime Medicine
- Wilson, AATD and CGD clinical progress anchors a broader editing and partnership pipeline.PRME
Corporate presentation - Prime Editing advances gene editing with broad clinical programs and pivotal data expected in 2027.PRMEMorgan Stanley 24th Annual Global Healthcare Conference
- Prime Editing advances versatile gene therapies with strong clinical and financial momentum.PRMEH.C. Wainwright 28th Annual Global Investment Conference
- Prime editing platform advances curative therapies for major genetic diseases and secures key partnerships.PRMECorporate presentation
- Net loss narrowed on lower expenses, but cash runway and funding remain key concerns.PRMEQ2 2026
- Prime Editing's modular platform advances curative therapies for major genetic diseases.PRMECorporate presentation
- Liver and cystic fibrosis programs prioritized, with INDs for Wilson’s and AATD on track for 2026.PRMEMorgan Stanley 23rd Annual Global Healthcare Conference
- Prime Editing advances genetic therapies with clinical milestones and strong partnerships ahead.PRMEGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Prime editing targets a curative therapy for Wilson disease, with clinical trials set for 2026.PRMEKOL Event
Next Prime Medicine earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
Prime Medicine
Next Prime Medicine earnings date
Jefferies Global Healthcare Conference16 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Prime Medicine, Inc. is a biotechnology company specializing in next-generation gene editing technologies aimed at developing curative therapies for a broad range of genetic diseases. The company utilizes its proprietary Prime Editing platform, a highly precise and versatile method of correcting disease-causing mutations in DNA, targeting nearly 90% of known genetic mutations. Prime Medicine's therapeutic focus includes areas like hematology, immunology, liver, ocular, and neuromuscular diseases. The company is headquartered in Cambridge, Massachussetts, and its shares are listed on the NASDAQ.